Drugs / tumor lysate-loaded autologous dendritic cells
tumor lysate-loaded autologous dendritic cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00280982 | Jan 2006 → Sep 2009 | malignant pleural mesothelioma | Erasmus Medical Center | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | tumor lysate-loaded autologous dendritic cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00280982 ↗ |
| Modality | Cell therapy | “Three doses of properly pulsed autologous dendritic cells are then re-injected every two weeks.” NCT00280982 ↗ |
| Route | Intravenous | “Ten patients with malignant pleural mesothelioma received three vaccinations of clinical-grade autologous dendritic cells intradermally and intravenously at 2-week intervals...” PMID 20167848 ↗ Feb 2010 |